Clinical experience with adalimumab in the treatment of ocular Behçet disease.
about
A Clinical Picture of the Visual Outcome in Adamantiades-Behçet's DiseaseAdalimumab in the management of Behçet's diseaseAn update on the use of biologic therapies in the management of uveitis in Behçet's disease: a comprehensive review.Ischemic retinal vasculitis and its management.Mimicry and deception in inflammatory bowel disease and intestinal behçet disease.Development of Immunopathogenesis Strategies to Treat Behçet's Disease.Update on the use of systemic biologic agents in the treatment of noninfectious uveitis.Update on the therapy of Behçet disease.Biological agents for the treatment of uveitis.Adalimumab for the treatment of Behçet's disease: experience in 19 patients.Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis.Current and future treatments for Behçet's uveitis: road to remission.Emerging drugs for the treatment of uveitis.Therapy of ocular Behçet disease.Ocular Involvement of Behçet's Syndrome: a Comprehensive Review.Behçet syndrome: from pathogenesis to novel therapies.Adalimumab for the treatment of uveitis.Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.Safety profile of biologic agents for Behçet's disease in a multicenter observational cohort study.Behçet's disease: review with emphasis on dermatological aspects.Retinal function and morphology in the rabbit eye after intravitreal injection of the TNF alpha inhibitor adalimumab.Etanercept therapy in Behçet's disease. The tight control strategy in refractory disease.Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related Uveitis.Long-term clinical outcomes in patients with refractory uveitis associated with Behçet disease treated with infliximab.Successful treatment with adalimumab in a familial case of gastrointestinal Behcet's diseaseAnti-TNF- therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients
P2860
Q26777598-3CD65C17-A5A4-4C6A-8D8C-357FC9B854D8Q26861428-B999014B-6E24-45E3-8FBA-7A5FE639CD11Q33910781-30867E41-4242-4BCE-9BD7-67AC235E12F7Q35170689-DEFD4EE0-09B4-46D0-94FD-B7E2E0E2B8AFQ35865662-F448718F-66FE-4FFD-B18F-FDA6CF1176B7Q35884889-810C7305-AC99-449F-94C5-AF0CCE355ADEQ37600483-B94E05A7-945E-493B-A4ED-463613B7252FQ37712230-138B2499-31BE-47E4-8AB9-2D0A50303574Q37984565-1AA62D81-4E7C-4265-9E07-D40FE41AB953Q38020828-EBC5BEDD-53DB-4812-B94C-5CD2FDFC51B2Q38074446-58500762-0095-4ECB-95AF-8EAA5404550EQ38111308-E2E82794-1B70-4DEE-BFFA-A5D7D3F2A90DQ38166016-5F173936-1030-4691-ACF5-CD2B9DACDFEBQ38174652-21285FD3-6C47-4753-B665-DBE43FB7BAACQ38211813-46B9A9A3-F657-4472-B10C-E4F4A523B0F2Q38275100-B22A7262-7CF9-4951-AF4A-D1283BAB1595Q39111626-32BCCDBA-5721-45AB-8A9A-D3D6AAE7E08CQ39181648-B2808F2A-8014-41A0-A3C2-9637F40C4C09Q40630984-4A8A613D-F084-4C13-8FC9-FC12324A1F7EQ41679943-2FAE58B9-AC77-4228-94D0-965C940A58BFQ43016617-BE02C7B8-C564-4790-83D2-BA5B8858F524Q44565138-C6A18C7A-23DA-417C-A3E4-8A274518739AQ48368367-2A217E50-7A50-4827-B951-21A54E378E32Q50938469-DDD8EB11-0A72-4F7A-B547-A6BD1616D6B5Q57612968-4D45128F-BB2B-4E8F-B7B2-BC9C36E05F86Q57767895-EF8736FE-6677-4DCE-8D8A-3E168FFCAB27
P2860
Clinical experience with adalimumab in the treatment of ocular Behçet disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical experience with adalimumab in the treatment of ocular Behçet disease.
@en
Clinical experience with adalimumab in the treatment of ocular Behçet disease.
@nl
type
label
Clinical experience with adalimumab in the treatment of ocular Behçet disease.
@en
Clinical experience with adalimumab in the treatment of ocular Behçet disease.
@nl
prefLabel
Clinical experience with adalimumab in the treatment of ocular Behçet disease.
@en
Clinical experience with adalimumab in the treatment of ocular Behçet disease.
@nl
P2860
P1476
Clinical experience with adalimumab in the treatment of ocular Behçet disease
@en
P2093
Ahmed Bawazeer
Lina H Raffa
P2860
P304
P356
10.3109/09273948.2010.483314
P577
2010-06-01T00:00:00Z